Hematological Disorders Overview: Lymphoma, CML, PMF, and Hyperleukocytosis

Uniqcret doctor knowledgesINMEDINMED HematoINMED ONCO
On this page

1. Anemia in Lymphoma: Mechanisms and Clinical Insight

Lymphoma, a malignancy of the lymphatic system, can lead to anemia through several distinct pathophysiological mechanisms:

1.1 Bone Marrow Infiltration

  • Mechanism: Lymphoma cells infiltrate the bone marrow and crowd out erythropoietic precursors.
  • Effect: Impaired hematopoiesis leads to pancytopenia, including normocytic normochromic anemia.
  • Diagnostic Clue: Bone marrow biopsy shows lymphoma cells replacing hematopoietic tissue.

1.2 Autoimmune Hemolytic Anemia (AIHA)

  • Common in: Non-Hodgkin lymphoma (especially CLL-like types).
  • Mechanism: The lymphoma drives production of autoantibodies against red cells.
  • Effect: Increased red cell destruction with spherocytes seen on smear, elevated LDH, indirect bilirubin, and reticulocytosis.
  • Confirmatory Test: Positive direct Coombs test.

1.3 Anemia of Chronic Disease (ACD)

  • Mechanism: Inflammatory cytokines (IL-6, TNF-α) interfere with iron metabolism, reducing erythropoietin response and trapping iron in macrophages.
  • Labs: Low serum iron, low TIBC, high ferritin.

1.4 Chemotherapy-Induced Anemia

  • Mechanism: Cytotoxic damage to proliferating marrow cells.
  • Management: Often managed supportively or with erythropoiesis-stimulating agents.

1.5 Nutritional Deficiencies

  • Mechanism: Poor appetite or GI toxicity may lead to deficiencies in folate, vitamin B12, or iron.

2. Peripheral Blood Smear: CML vs. PMF

A core hematology diagnostic skill is distinguishing CML (Chronic Myeloid Leukemia) from PMF (Primary Myelofibrosis) based on PBS findings:

FeatureCMLPMF
WBC CountVery high (>100,000/µL)Normal to mildly elevated (early), decreased in late
Granulocytic SeriesFull spectrum of myeloid precursors: "myelocyte bulge"Left shift with nRBCs and immature myeloids
BasophiliaPresentRare
PlateletsOften highGiant platelets; variable count
Teardrop CellsRareClassic feature of PMF
LeukoerythroblastosisRarePresent
Blasts in Chronic Phase<10%Mild
Bone MarrowHypercellular with myeloid hyperplasiaFibrotic with abnormal megakaryocytes


3. Splenomegaly: CML vs. PMF

CML:

  • Massive splenomegaly due to infiltration by proliferating granulocytes and extramedullary hematopoiesis.
  • Often presents with left upper quadrant fullness or early satiety.
  • Very high WBC count accompanies splenomegaly.

PMF:

  • Splenomegaly due to extramedullary hematopoiesis secondary to bone marrow fibrosis.
  • WBC count not typically extremely elevated, and may fall in late stages.

4. Hyperleukocytosis Syndrome

4.1 Definition

  • WBC > 100,000/µL.
  • Most common in acute leukemias (AML, ALL) and CML blast crisis.

4.2 Pathophysiology

  • Large, rigid leukemic blasts occlude small vessels → microcirculatory stasis.
  • Affects high-flow areas like brain and lungs → organ dysfunction.

4.3 Clinical Manifestations

  • CNS: Headache, dizziness, confusion, seizures, coma.
  • Lungs: Dyspnea, hypoxia, acute respiratory failure.
  • Other: Priapism, visual disturbances, renal failure (TLS).

4.4 Management

  • Emergency!
  • Start with hydration (0.9% saline) to prevent tumor lysis and renal failure.
  • Avoid transfusing PRBCs unless symptomatic anemia exists.
  • Leukapheresis: Immediate cytoreduction.
  • Hydroxyurea: 50–100 mg/kg/day for cytoreduction.
  • Rasburicase/allopurinol: Prevent tumor lysis syndrome.
  • Start definitive chemotherapy once stable.

5. Diagnostic Criteria for Chronic Myeloid Leukemia (CML)

5.1 Clinical Features

  • Fatigue, weight loss, night sweats, splenomegaly.
  • Hypermetabolism due to high cell turnover.

5.2 Peripheral Blood Findings

  • Leukocytosis >100,000 cells/µL.
  • Full spectrum of myeloid precursors.
  • Basophilia and eosinophilia.
  • Thrombocytosis (early); thrombocytopenia (late).

5.3 Bone Marrow

  • Hypercellular with granulocytic hyperplasia.
  • Increased myeloid:erythroid ratio.
  • Giant, dysplastic megakaryocytes.

5.4 Cytogenetic & Molecular Testing

  • Philadelphia chromosome: t(9;22)(q34;q11).
  • BCR-ABL1 fusion gene → constitutively active tyrosine kinase.
  • Detected via FISH, PCR, or karyotyping.

5.5 Phases of CML

PhaseBlast %Clinical Picture
Chronic<10%Stable, asymptomatic or mild symptoms
Accelerated10–19%Symptoms worsen, resistant to therapy
Blast Crisis≥20%Resembles acute leukemia, poor prognosis

5.6 Ancillary Tests

  • LDH: Elevated from high turnover.
  • Uric acid: High, risk of gout or TLS.
  • CBC + smear: Essential for monitoring.

6. Summary Table

DisorderKey FeaturePBSSplenomegalyGenetic Hallmark
CMLMyeloid cell proliferationMyelocyte bulge, basophiliaMassiveBCR-ABL1 (t9;22)
PMFMarrow fibrosisTeardrop cells, nRBCsMassiveJAK2/CALR/MPL mutations
LymphomaLymphatic malignancyAnemia, possibly AIHAPossibleVaries by type
HyperleukocytosisWBC >100,000Blasts (AML/ALL)May be presentOften no specific cytogenetics; depends on leukemia


🧠 Medical Student Takeaways

  • Memorize PBS patterns to distinguish CML from PMF.
  • Recognize anemia mechanisms in cancer: marrow infiltration, hemolysis, chronic inflammation.
  • Treat hyperleukocytosis as a true hematologic emergency.
  • Know that BCR-ABL1 fusion is pathognomonic for CML, and targeted therapy with TKIs (e.g., imatinib) revolutionized its treatment.
0
Message for International and Thai ReadersUnderstanding My Medical Context in ThailandRead more →Message for International and Thai ReadersUnderstanding My Broader Content Beyond MedicineRead more →

Comments

No comments yet. Be the first to share your thoughts.

Sign in to comment